Halozyme Therapeutics EBITDA 2010-2025 | HALO

Halozyme Therapeutics EBITDA for the quarter ending March 31, 2025 was $0.162B, a 40.71% increase year-over-year.

  • Halozyme Therapeutics 2024 EBITDA was 0.629B, a 48.61% increase from 2023.
  • Halozyme Therapeutics 2023 EBITDA was 0.423B, a 29.84% increase from 2022.
  • Halozyme Therapeutics 2022 EBITDA was 0.326B, a 14.51% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Halozyme Therapeutics EBITDA 2010-2025 | HALO

  • Halozyme Therapeutics 2024 EBITDA was 0.629B, a 48.61% increase from 2023.
  • Halozyme Therapeutics 2023 EBITDA was 0.423B, a 29.84% increase from 2022.
  • Halozyme Therapeutics 2022 EBITDA was 0.326B, a 14.51% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.